Product
Ciclesonide
Name
Alvesco
INN Name
ciclesonide
FDA Approved
Yes
3 clinical trials
3 organizations
2 indications
3 documents
Indication
Allergic RhinitisIndication
COVID-19Clinical trial
A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled CiclesonideStatus: Completed, Estimated PCD: 2008-04-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 InfectionStatus: Completed, Estimated PCD: 2021-01-05
Clinical trial
PROphylaxis for paTiEnts at Risk of COVID-19 infecTionStatus: Recruiting, Estimated PCD: 2024-07-01
Document
DailyMed Label: AlvescoOrganization
Physicians Total Care, Inc.Document
DailyMed Label: OmnarisOrganization
Covis Pharma US, IncDocument
DailyMed Label: ZetonnaOrganization
Sixarp, LLC